Novel therapy may prove effective in treatment of 30 percent of cancers

Thursday, May 14, 2009 - 02:49 in Health & Medicine

A ground-breaking Canada-wide clinical trial led by Dr Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Universite de Montreal, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer...

Read the whole article on

More from

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net